Bill & Melinda Gates Foundation

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

La Ruche Health provides an innovative platform that connects patients with virtual and at-home healthcare services. Utilizing health AI technology, it offers advice and facilitates the booking of medical services and lab tests through user-friendly applications on iOS, Android, and WhatsApp. The company has recognized WhatsApp as a key distribution channel, being the first to integrate generative AI into this platform to enhance conversational experiences, particularly for low-literacy communities. Additionally, La Ruche Health develops a medical record management system that enables healthcare teams to efficiently manage and exchange medical data through both web and mobile applications. This comprehensive platform allows for virtual and physical consultations, as well as access to a wellness marketplace designed to make modern health services more affordable and accessible to various communities.

ApiJect Systems is a medical technology company focused on revolutionizing the delivery of injectable medications through its innovative platform for prefilled, single-dose injectors. By utilizing medical-grade plastic resin, ApiJect replaces traditional materials like glass and rubber, streamlining the manufacturing process and significantly reducing environmental impact. The ApiJect Platform enables pharmaceutical and biotech companies to efficiently produce scalable prefilled injectors, either on proprietary Blow-Fill-Seal packaging lines or through partnerships with other manufacturers. This approach not only simplifies the supply chain but also accelerates production times, transforming a multi-step process that typically takes weeks into a rapid, efficient operation. Through these advancements, ApiJect aims to make prefilled injections more affordable and accessible to patients globally.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Bayer is a multinational corporation with a focus on life science industries. It operates in three main business areas: Pharmaceuticals, Consumer Health, and Crop Science. Bayer Pharmaceuticals develops and markets a wide range of medicines, including those for cardiovascular diseases, oncology, and women's health. The Consumer Health division offers over-the-counter products and medical devices, while Crop Science provides crop protection products, seeds, and digital farming solutions. Bayer Animal Health, a part of the Crop Science division, is a global leader in animal health, offering a broad portfolio of products for the treatment and prevention of diseases in livestock and companion animals. The company's global presence and extensive product portfolio enable it to address various health challenges in humans, animals, and crops, contributing to a sustainable future.

Nuvisan is a global provider of pharmaceutical research services, based in Neu-Ulm, Germany. The company operates as a fully integrated contract research organization (CRO) and offers a wide range of product development and support services to the pharmaceutical, biotechnology, and medical device industries. Nuvisan's expertise encompasses early and clinical development, drug trials, bioanalytical analysis, pharmaceutical analysis, quality control, stability testing, and the management of test specimens. By delivering both individual tests and comprehensive drug development programs, Nuvisan supports clients throughout the various stages of drug development, facilitating the advancement of new therapies and medical innovations.

Celanese is a global technology and specialty materials company that engineers and manufactures a diverse range of products essential for everyday living. It is one of the world’s largest producers of acetic acid and its derivatives, which play a crucial role in various industries, including coatings and adhesives. Additionally, Celanese produces specialty polymers utilized in automotive, electronics, medical, building, and consumer markets. The company also manufactures cellulose derivatives, notably used in cigarette filters. With a strong commitment to research and development, Celanese focuses on innovation and provides opportunities for growth and advancement within a performance-driven culture. Its products are integral to the food, beverage, and pharmaceutical industries, reflecting the company's broad impact on daily life.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Iconovo AB, based in Lund, Sweden, specializes in developing and licensing inhalation devices. It offers a range of dry powder inhalers, including ICOres, ICOcap, ICOone, and ICOpre, catering to generic pharmaceutical companies. With a focus on technical innovation, user-friendly design, and cost-efficiency, Iconovo aims to become a global leader in its field, targeting a multimillion turnover within five years.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on enhancing healthcare access in rural Africa by developing and distributing AI-powered diagnostic devices. These compact devices are designed for primary care doctors in peri-urban and rural clinics, providing accurate and affordable diagnostic services. Ilara Health integrates its technology within a proprietary platform that connects to an electronic medical record system, allowing healthcare providers to efficiently record and manage patient data. By leveraging existing healthcare infrastructure, Ilara Health aims to improve the accessibility and affordability of diagnostic services in underserved regions.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Credence MedSystems, Inc. is a drug delivery and specialty pharmaceutical company based in Menlo Park, California, focused on enhancing the safety of injectable medications for patients and caregivers. The company develops innovative products, including the Companion Staked Needle Syringe, Companion Luer Syringe, and the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable mechanism for safer use. Credence MedSystems aims to simplify the commercialization process for pharmaceutical partners by integrating advanced safety features into existing drug delivery systems without necessitating significant changes to their manufacturing processes. This approach, termed "Innovation Without Change," allows for a more efficient path to market while ensuring that the delivery systems meet high standards of safety and efficacy. The company, formerly known as SafeShot Technologies, Inc., was established in 2011 and has formed a strategic collaboration with SCHOTT AG to further enhance its product offerings.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.

Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a range of products that includes lactoferrin and lysozyme glycoproteins, which are utilized for gastrointestinal health and the dietary management of acute diarrhea, as well as for treating topical infections and fungal conditions. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and operates a BioShare program that grants researchers access to recombinant proteins and peptides for various research applications. The company leverages its patented ExpressTec technology, which enhances recombinant protein yield through a plant-based manufacturing process, enabling the development of new biotherapeutics, vaccines, and other biomanufacturing reagents.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.

Takeda Ventures, established in 2001, is the venture capital arm of Takeda Pharmaceutical Company Limited. Based in Cambridge, Massachusetts, with additional offices in San Diego, California, and globally, the firm specializes in direct and fund-of-fund investments, focusing on seed to mid-stage biotechnology and pharmaceutical companies. Takeda Ventures invests in therapeutics, including cardiovascular, inflammatory, metabolic, and oncological diseases, as well as regenerative medicines and novel technologies like RNA and DNA modulation. It typically invests between $0.25 million to $5 million, preferring minority stakes and board observer roles, and co-invests with other venture capital firms. Additionally, Takeda Ventures facilitates preclinical therapeutic discovery alliances and invests in digital health companies that improve patient outcomes and care delivery.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.